BD Spinout embecta Targets Diabetes Market With Three-Pronged Growth Strategy
Diabetes pure play embecta, spun out of BD, is a leading force in the global insulin syringe and pen cap arena, but the company has a comprehensive plan to enter higher-growth device markets, including automated insulin delivery (via a patch pump) and, potentially, smart insulin pens. We discuss the company’s growth strategy at length with CEO Dev Kurdikar.
Read Article